Original articleTopical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia
Section snippets
Study Population
The institutional review board of the University of Miami approved this retrospective study, and the methods adhered to the tenets of the Declaration of Helsinki and complied with the Health Insurance Portability and Accountability Act. Pharmacy records identified 64 patients who received 5-FU as a treatment for OSSN between May 2004 and March 2015. Some patients were excluded because they were prescribed topical 5-FU as adjuvant surgical therapy (n = 3), did not complete therapy (n = 14), or
Results
Demographics of the study population are presented in Table 1. As in previous studies, most patients were white men in their seventh decade of life (Table 1).
Discussion
5-Fluorouracil was first reported as a treatment for OSSN in 1986.39 Since then, a few case series and small reports have been published, with an overall response frequency ranging from 57% to 100% for 5-FU treatment, which seems rather low.15, 39, 40, 41 However, when examining only cases treated with 5-FU as an exclusive primary therapy (as opposed to adjuvant therapy after surgical removal), the response frequency improves, ranging from 85% to 100%.4, 15, 39, 40, 41 In our study,
References (47)
- et al.
Ocular surface squamous neoplasia
Surv Ophthalmol
(1995) - et al.
Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors
Ophthalmology
(2004) - et al.
Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia
Ophthalmology
(1997) - et al.
Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience
Ophthalmology
(1997) - et al.
Subconjunctival/perilesional recombinant interferon alpha2b for ocular surface squamous neoplasia: a 10-year review
Ophthalmology
(2010) - et al.
5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea
Ophthalmology
(2000) - et al.
Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea
Ophthalmology
(1995) - et al.
Redefining the role of interferon in the treatment of malignant diseases
Eur J Cancer
(2010) - et al.
Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b
Am J Ophthalmol
(2014) - et al.
Interferon treatment for corneolimbal squamous dysplasia
Am J Ophthalmol
(1998)
Topical interferon alpha-2b as a single therapy for primary ocular surface squamous neoplasia
Asia Pac J Ophthalmol (Phila)
Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications
Ophthalmology
Mitomycin C therapy for corneal intraepithelial neoplasia
Am J Ophthalmol
Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C
Am J Ophthalmol
Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma
Am J Ophthalmol
Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia
Am J Ophthalmol
Topical chemotherapy with 5-fluorouracil. A review
J Am Acad Dermatol
High-resolution optical coherence tomography as an adjunctive tool in the diagnosis of corneal and conjunctival pathology
Ocul Surf
Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture
Arch Ophthalmol
Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil
Br J Ophthalmol
Excision and cryosurgery in the treatment of conjunctival malignant epithelial tumours
Eye (Lond)
The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation
Cornea
Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012
Cornea
Cited by (75)
Personalized treatment concepts in extraocular cancer
2024, Advances in Ophthalmology Practice and ResearchTopical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment
2024, Asia-Pacific Journal of OphthalmologyTopical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study
2023, Ocular SurfaceCitation Excerpt :Across the literature, treatment regimens have varied. Our typical regimen was four times a day for one week on with three weeks off, yet others have used cycles ranging from two to seven days on with 30–45 days off treatment [30,36,37]. Our patients received an average of four treatment cycles until clinical resolution (Fig. 3), which also falls within the range reported in the literature of two to six months [27,37].
Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells
2022, American Journal of OphthalmologyCitation Excerpt :Our in vitro data expands on the finding that although topical MMC enacts a cytotoxic effect on SC, it does so at a concentration that is significantly toxic to the surrounding corneal LSCs. Topical 5-FU is used empirically for ocular adnexal SC, presumably because it has excellent efficacy in ocular surface squamous neoplasia, tolerable side effects, and affordable costs.13,25 However, we found a large discrepancy comparing the 5-FU doses that reduce SC viability vs LSC viability (approximately 300-fold higher concentration to kill 50% of SC cells).
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Supported by the Department of Veterans Affairs (A.G.); the Veterans Health Administration (A.G.); the Office of Research and Development (A.G.); Clinical Sciences Research and Development's Career Development Award (grant no.: CDA-2-024-10S [A.G.]); the National Institutes of Health, Bethesda, Maryland (Center Core grant no.: P30EY014801 [C.L.K.]); Research to Prevent Blindness, Inc., New York, New York (unrestricted grant [C.L.K.]); the US Department of Defense (grant no.: W81XWH-09-1-0675 [A.G.]); the Ronald and Alicia Lepke Grant (C.L.K.); the Lee and Claire Hager Grant (C.L.K.); the Gordon Charitable Trust (C.L.K.); the Robert Baer Family Grant (C.L.K.); and the Jimmy and Gaye Bryan Grant (C.L.K.); and Grants – Florida Lions Eye Bank, Miami FL.
Author Contributions:
Conception and design: Galor, Karp
Analysis and interpretation: Joag, Sise, Galor, Karp
Data collection: Joag, Sise, Murillo, Ahmed, Wong, Mercado, Galor, Karp
Obtained funding: none
Overall responsibility: Joag, Sise, Galor, Karp